Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wanjia Group Holdings OCF Margin % Historical Data
* Premium members only.
The historical data trend for Wanjia Group Holdings's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00401 vs MCK, COR, CAH: OCF Margin % Comparison
For the Medical Distribution subindustry, Wanjia Group Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanjia Group Holdings OCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Wanjia Group Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Wanjia Group Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wanjia Group Holdings (HKSE:00401) has a OCF Margin % of -12.95% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Wanjia Group Holdings and its competitors. According to the industry distribution chart, Wanjia Group Holdings ranks #93 out of 117 companies in the Medical Distribution industry, placing it in the top 79.5%.
Is Wanjia Group Holdings' OCF Margin % too high?
Wanjia Group Holdings' current OCF Margin % is -12.95%. Based on the distribution chart, Wanjia Group Holdings ranks #93 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Wanjia Group Holdings has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wanjia Group Holdings' OCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Wanjia Group Holdings ranks #93 out of 117 companies for OCF Margin %. This places Wanjia Group Holdings in the lower half of its industry. The industry median OCF Margin % is 1.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Distribution company?
The median OCF Margin % among Medical Distribution companies is 1.99, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Wanjia Group Holdings and its competitors. For the Medical Distribution industry, the median OCF Margin % is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanjia Group Holdings's current OCF Margin % is -12.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanjia Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wanjia Group Holdings (HKSE:00401) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.13 — trading 116.7% above its estimated fair value. The current OCF Margin % is -12.95%. Wanjia Group Holdings' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Wanjia Group Holdings (HKSE:00401), the current OCF Margin % is -12.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanjia Group Holdings (HKSE:00401) Overvalued in 2026?
Based on GuruFocus' analysis, Wanjia Group Holdings stock appears to be overvalued.
The current stock price of HK$0.13 is trading 116.7% above its estimated GF Value™ of HK$0.06.
GuruFocus considers Wanjia Group Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00401:
OCF Margin %: -12.95%
GF Value™: HK$0.06 vs. price of HK$0.13 (116.7% above fair value)
No single metric tells the full story. See the HKSE:00401 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanjia Group Holdings Ltd is an investment holding company. Along with its subsidiaries, the company operates in principal activities of Pharmaceutical wholesale and distribution business, and Hemodialysis treatment and consultancy service business. The company generates key revenue from the Hemodialysis treatment and consultancy service business. Geographically, company operates in Hong Kong and China, having majority revenue generation from Mainland China.
35GF Score
Get the complete analysis for HKSE:00401
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00401 has been successfully added to your 
